Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 19/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 19/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 13/20 | 0.66 |
| ▸ | ADORA2B | P29275 | 11/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL7224612 | 0.98 | ADORA3 (0.67) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL7012704 | 0.96 | ADORA3 (0.72) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL1982965 | 0.96 | ADORA3 (0.72) | ADORA3ADORA2AADORA1ADORA2B | |
| Hydrochloric Acid SCHEMBL5089282 | 0.95 | ADORA3 (0.71) | ADORA3ADORA2AADORA1ADORA2B | |
| Maleic Acid SCHEMBL7223381 | 0.93 | ADORA3 (0.65) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL7228509 | 0.91 | ADORA3 (0.58) | ADORA3ADORA2AADORA1ADORA2B | |
| Carboxynaphthol SCHEMBL7223449 | 0.87 | ADORA3 (0.59) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL7456601 | 0.87 | ADORA3 (0.58) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL7223384 | 0.86 | ADORA3 (0.56) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL5093477 | 0.86 | ADORA3 (0.57) | ADORA3ADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6528494-B2 | Antiinflammatory agents | COX BRIAN (GB) | 2003-03-04 | — | — | US | disclosed |
| EP-0948509-B1 | 2-(PURIN-9-YL)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES | GLAXO GROUP LTD (GB) | 2002-10-16 | — | — | EP | disclosed |
| US-6426337-B1 | ANTIINFLAMMATORY AGENTS | SMITHKLINE BEECHAM CORPORATION | 2002-07-30 | — | — | US | disclosed |
| US-20020086850-A1 | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives | COX BRIAN (GB) | 2002-07-04 | — | — | US | disclosed |
| EP-0948509-A1 | 2-(PURIN-9-YL)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998028319-A1 | 2-(PURIN-9-YL)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086850-A1 | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives | PURB, P2RX3, P2RY2 | ADORA3 182/4885ADORA2A 202/4885ADORA1 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.